Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Derma Sciences ($DSCI) Raises $19.7 million

Top

Daily Dose Newsroom Index

Search Daily Dose & Film Annex

BIO SmartBrief

Daily Dose Newsletter

Tuesday

Apr032012

Derma Sciences ($DSCI) Raises $19.7 million

DDE Editor

Derma Sciences (NASDAQ: DSCI) raised $19.7 million through the sale of 2.1 million shares at $9.25 in a follow-on underwritten by Piper Jaffray. Derma plans to begin Phase III testing next half of DSC127 for diabetic foot ulcers. The compound is an angiotensin analog. Derma also markets dressings for wounds and burns.

DSC127 is an analog of a naturally occurring peptide, Angiotensin. It has been shown to increase keratinocyte proliferation, increase extracellular matrix production, and increase vascularization. Additionally, histological examination has shown that DSC127 accelerated collagen deposition six-fold. All these help to accelerate dermal tissue repair. One potential method of action is the up-regulation of mesenchymal stem cells (MSCs) at the site of injury. MSCs originate in the human embryo and are considered to be multipotent — a type of stem cell that has not yet adopted a specific cellular phenotype. Such cells have the ability to differentiate into various types of cells found within the human body, including fibroblasts, adipose cells, muscle cells, bone cells, and skin cells.

The patented amino acid peptide DSC127 optimizes the well published wound healing capabilities of Angiotensin while removing all blood pressure effects of the compound.

Extensive pre-clinical studies have demonstrated the efficacy of the compound in accelerating healing and reducing scar formation. Pre-clinical studies thus far have shown:

Improved in-growth of host tissue into artificial skins
Accelerated healing in full thickness skin excision wounds in rats and diabetic mice
Accelerated healing in partial thickness thermal injuries in guinea pigs
Accelerated healing in a random flap skin model in rats Improved scar reduction in rats

Phase 1 is completed and top line Phase 2 data appears to have been presented last fall. The next step will be pivotal (phase III) studies.

View the full DSCI chart at Wikinvest

References (4)

References allow you to track sources for this article, as well as articles that were written in response to this article.

Response: B2B Marketing Strategies

at B2B Marketing Strategies on November 24, 2013

Wonderful Site, Keep up the good work. Thank you.
Response: el dominio

at el dominio on March 26, 2014

Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Derma Sciences ($DSCI) Raises $19.7 million
Response: AlphaGenix

at AlphaGenix on July 2, 2014

Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Derma Sciences ($DSCI) Raises $19.7 million
Response: testosterone supplement boca florida

at testosterone supplement boca florida on July 28, 2014

Daily Dose Equities - Wall Street Analysis for Biomedical Research - Daily Dose Newsroom - Derma Sciences ($DSCI) Raises $19.7 million

Reader Comments

There are no comments for this journal entry. To create a new comment, use the form below.

Post a New Comment

Enter your information below to add a new comment.

My response is on my own website »

Author:

Author Email (optional):

Author URL (optional):

Post:

↓ | ↑

Some HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>

Copyright by Daily Dose Equities. All rights reserved. This website contains information and opinions based on data obtained from reliable sources, which is current as of the publication date, and does not constitute a recommendation that any of the securities mentioned herein are appropriate for any specific individual circumstances and does not guarantee that future results or performance will match those predicted to occur. Although every effort is made to ensure the accuracy and completeness of the information on this website by using reliable data sources such as SEC filings and press releases, no guarantees are made in this regard as it has not been reviewed or certified by an independent auditor and may also include the opinions and future projections of the author. The contributing authors on this website are not chartered financial analysts, registered investment advisors or broker/dealers, and do not provide individual investment advice. The information provided by the writers on this website is for informational purposes only and should not be construed as an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular trading strategy in any jurisdiction. The information appearing on this website, blog, and related publications has not been reviewed or endorsed by any of the companies mentioned and should not be regarded as offical corporate news, publications, or shareholder communications. Film Annex Capital Partners, LLC (FACP) is the owner of this website and they provide strategic advisory, social media, and marketing services to emerging-growth companies. A number of the companies displayed on this site may be current or previous clients of FACP. In most instances, FACP has received fees for services for the creation, preparation and distribution of materials featured on this site, which are paid for in cash and/or stock, by the featured company ("client"). More detailed disclosure regarding fees paid is available upon request. FACP is not a broker/dealer or registered investment advisor. Information contained throughout this site is not an offer to buy or sell securities. Information presented on this site is solely for informative purposes, and is not intended, nor should they be construed, as investment advice. The information provided including news, blogs, corporate profiles, and other material is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country. The companies featured on this site are typically development-stage and investment in such securities is considered highly speculative and carries a high degree of risk. Complete loss of capital is a distinct possibility. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at www.sec.gov and the Financial Industry Regulatory Authority (FINRA) at www.finra.org. Opinions stated herein may be solely FACP or the indicated source's, and not necessarily those of the featured Company. Officers, directors, and employees of FACP and financial analysts mentioned, and/or members of their families, may hold a position and may, from time to time, trade in these securities for their own accounts. Specific information in this regard will be furnished upon request. Trademarks are the property of their respective owners. 2010-12 Film Annex Capital Partners, LLC. All rights reserved.

Fill out your e-mail address to receive the DDE newsletter.
E-mail:
First:
Last: